C
Amneal Pharmaceuticals, Inc. AMRX
$10.48 $0.121.16% NASDAQ
Recommendation
Prev Close
$10.36
Volume
1,617,401
Avg Vol (90D)
1,658,742
Market Cap
$3.25B
Dividend & Yield
--
52-Week Range
$6.69 - $10.68
P/E (TTM)
1,233.33
EPS (TTM)
$0.0084
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Lesser-Known Healthcare Names With Major Upside in Store
10/2/2025 - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings
10/8/2025 - MarketBeat
Amneal Pharmaceuticals (AMRX, $10.36) RSI Indicator left the overbought zone on October 07, 2025
10/8/2025 - Tickeron - Stocks
Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025?
10/7/2025 - Simply Wall St
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
10/7/2025 - Zacks Investment Research
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
10/6/2025 - Nasdaq News: Stocks
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
10/6/2025 - Zacks Investment Research
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab)
10/6/2025 - Business Wire
A Look at Amneal Pharmaceuticals (AMRX) Valuation Following Regulatory Pipeline Milestones and FDA Approvals
10/5/2025 - Simply Wall St
Amneal (AMRX) Strengthens Pipeline With FDA Advances but What Does This Mean for Its Growth Ambitions?
10/3/2025 - Simply Wall St
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
10/3/2025 - Zacks Investment Research
Amneal Pharmaceuticals (AMRX, $10.4) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 2, 2025
10/3/2025 - Tickeron - Stocks
Amneal Pharmaceuticals (AMRX, $10.38) RSI Indicator left the overbought zone on October 01, 2025
10/2/2025 - Tickeron - Stocks
Amneal Pharmaceuticals (AMRX, $10.38) price may drop as it broke higher Bollinger Band on Oct 01, 2025
10/2/2025 - Tickeron - Stocks
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10/2/2025 - Zacks Investment Research
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High - Should You Buy?
10/1/2025 - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR Biosimilar, Targets Multi-Billion-Dollar Market
10/1/2025 - Yahoo! Finance: News
Amneal to Report Third Quarter 2025 Results on October 30, 2025
9/30/2025 - Globe Newswire
Amneal Pharmaceuticals (AMRX, $9.87) entered Uptrend as Momentum indicator ascends above 0 level on Sep 29, 2025
9/30/2025 - Tickeron - Stocks
Amneal Pharmaceuticals (AMRX, $9.87) Stochastic Oscillator left the oversold zone on September 29, 2025
9/30/2025 - Tickeron - Stocks
12 Healthcare Stocks with Insider Buying in 2025
9/29/2025 - Insider Monkey
Amneal Pharmaceuticals (AMRX) Targets US Approval for Xolair Rival
9/26/2025 - GuruFocus
Amneal Pharmaceuticals (AMRX) Seeks FDA Approval for Xolair Biosimilar
9/26/2025 - GuruFocus
Amneal Pharmaceuticals (AMRX) Seeks FDA Approval for XOLAIR Biosimilar
9/26/2025 - GuruFocus
Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR
9/26/2025 - The Fly
Income Statement
Total Revenue (TTM)
$2.85B
EBITDA (TTM)
$625.08M
EBIT (TTM)
$379.72M
Net Income (TTM)
$3.38M
Balance Sheet
Total Assets (Q)
$3.42B
Total Debt (Q)
$2.58B
Total Liabilities (Q)
$3.47B
Book Value Per Share (Q)
-$0.357
Cash Flow
Cash from Operations (TTM)
$351.08M
Cash from Investing (TTM)
-$81.12M
Cash from Financing (TTM)
-$234.40M
Net Change in Cash (TTM)
$34.05M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
0.95
7-Day Total Return
6.18%
30-Day Total Return
11.73%
60-Day Total Return
26.72%
90-Day Total Return
43.17%
Year to Date Total Return
35.05%
1-Year Total Return
21.02%
2-Year Total Return
161.35%
3-Year Total Return
416.26%
5-Year Total Return
131.35%
52-week Low
Apr 10, 2025 - $6.69
52-week High
Oct 03, 2025 - $10.68
Valuation
Market Cap
$3.25B - Mid Cap
Enterprise Value
$5.83B
Price/Sales (TTM)
1.17
Price/Book (Q)
-29.02
Dividends and Shares
Shares Outstanding
322.36
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.amneal.com
Phone Number
908 947 3120
Address
400 Crossing Boulevard
Bridgewater, NJ 08807
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical... more
NASDAQ 10/08/2025 4:00PM Eastern Quotes delayed